Immunometabolism in systemic lupus erythematosus

Area of Science:

• Immunology
• Metabolic pathways
• Autoimmune diseases

Background:

• Systemic lupus erythematosus (SLE) is a complex autoimmune disease marked by inflammation, tissue damage, and autoantibody production.
• Immune metabolic dysregulation is increasingly recognized as a critical factor in SLE pathogenesis.
• Metabolic reprogramming in immune cells significantly impacts disease development and progression.

Purpose of the Study:

• To review current findings on immune cell metabolism in SLE.
• To highlight the role of metabolic disturbances and mitochondrial dysfunction in SLE pathogenesis.
• To explore therapeutic strategies targeting metabolic pathways for SLE treatment.

Main Methods:

• Synthesis of current research on immune cell metabolism in animal models of lupus and human SLE patients.
• Analysis of alterations in key metabolic pathways like glycolysis and oxidative phosphorylation.
• Examination of the interplay between metabolic dysregulation, mitochondrial function, and disease.

Main Results:

• Metabolic reprogramming profoundly affects immune cell activation, differentiation, and function in SLE.
• Dysregulation in glycolysis and oxidative phosphorylation contributes to inflammation and tissue injury.
• Mitochondrial dysfunction is closely linked to SLE pathogenesis.

Conclusions:

• Immune metabolic dysregulation is a key driver of SLE.
• Targeting metabolic pathways presents a potential therapeutic avenue for managing SLE and reducing organ damage.
• Further research into immune cell metabolism could lead to novel treatments for SLE.